Vital Farms' plan to narrow price gaps with other outdoor-access eggs is basically an admission that its premium brand has been damaged, deepening a bad negative feedback loop. Management says it is acting with urgency to restore volume growth by cutting the premium to reaccelerate sales velocity, and the stock fell 22% premarket. Its premium positioning leaves it highly exposed to the social-media backlash it failed to take seriously; the problem is not unresolvable but looks hard to fix. x.com  … Show more

Vital Farms might be in serious trouble as egg prices fall and its premium over regular eggs erodes, after a badly timed buyback and expansion. It drew its revolver and took an expensive Silver Point term loan that will crush free cash flow, and mothballed its new plant. EBITDA of $0-10M this year, against an EV over $600M, does not cover interest. Even normalized, it trades at 10-15x EBITDA for a commodity, versus single digits for Cal-Maine. Only another big bird-flu outbreak would rescue it. … Show more

China SXT Pharmaceuticals is a short-squeeze candidate: short interest exceeds 20%, institutional ownership exceeds 100%, no shares are left to borrow and the cost to borrow is over 500%. It has the same setup as other low-float, high-short-interest plays; after coiling all day, a pop on incoming volume is only a matter of time because shorts are trapped. x.com  x.com 

Wendy's, Xerox and Icahn Enterprises are set up for a short squeeze. They are the only stocks with over 30% short interest that pay dividends above 7%, so shorts pay heavily to stay short and lose more if prices rise. All three are in Stage 2 uptrends, and Wendy's and Xerox are retesting recent high-volume breakouts. A short-covering summer could start if the market breaks higher out of its consolidation. x.com